Genetic and environmental factors in Alzheimer's and Parkinson's diseases and promising therapeutic intervention via fecal microbiota transplantation. - 2021
Neurology; Neurology (clinical); Cellular and Molecular Neuroscience
Abstract :
[en] Neurodegenerative diseases are characterized by neuronal impairment and loss of function, and with the major shared histopathological hallmarks of misfolding and aggregation of specific proteins inside or outside cells. Some genetic and environmental factors contribute to the promotion of the development and progression of neurodegenerative diseases. Currently, there are no effective treatments for neurodegenerative diseases. It has been revealed that bidirectional communication exists between the brain and the gut. The gut microbiota is a changeable and experience-dependent ecosystem and can be modified by genetic and environmental factors. The gut microbiota provides potential therapeutic targets that can be regulated as new interventions for neurodegenerative diseases. In this review, we discuss genetic and environmental risk factors for neurodegenerative diseases, summarize the communication among the components of the microbiota-gut-brain axis, and discuss the treatment strategy of fecal microbiota transplantation (FMT). FMT is a promising treatment for neurodegenerative diseases, and restoration of the gut microbiota to a premorbid state is a novel goal for prevention and treatment strategies.
Disciplines :
Veterinary medicine & animal health
Author, co-author :
Wang, Hui ; Department of Toxicology, School of Public Health, Lanzhou University, Lanzhou, Gansu, China. huiwang@lzu.edu.cn ; Lanzhou Institute of Husbandry and Pharmaceutical Sciences of Chinese Academy of Agricultural Sciences, Lanzhou, Gansu, China. huiwang@lzu.edu.cn
Yang, Feng; Lanzhou Institute of Husbandry and Pharmaceutical Sciences of Chinese Academy of Agricultural Sciences, Lanzhou, Gansu, China
Zhang, Shidong; Lanzhou Institute of Husbandry and Pharmaceutical Sciences of Chinese Academy of Agricultural Sciences, Lanzhou, Gansu, China
Xin, Ruihua ; Université de Liège - ULiège > TERRA Research Centre ; Lanzhou Institute of Husbandry and Pharmaceutical Sciences of Chinese Academy of Agricultural Sciences, Lanzhou, Gansu, China
Sun, Yan; Lanzhou Institute of Husbandry and Pharmaceutical Sciences of Chinese Academy of Agricultural Sciences, Lanzhou, Gansu, China. sunyan_01@126.com
Language :
English
Title :
Genetic and environmental factors in Alzheimer's and Parkinson's diseases and promising therapeutic intervention via fecal microbiota transplantation.
This work was supported by a grant from the National Natural Science Foundation of China (No. 31802256) and Gansu Province Science Fund for Distinguished Young Scholars (No. 20JR5RA579) that was granted to Hui Wang.
Bianchi, V. E., Herrera, P. F. & Laura, R. Effect of nutrition on neurodegenerative diseases. A systematic review. Nutr. Neurosci. https://doi.org/10.1080/1028415X.2019.1681088 (2019).
Vaquer-Alicea, J. & Diamond, M. I. Propagation of protein aggregation in neurodegenerative diseases. Annu. Rev. Biochem. 88, 785–810 (2019). DOI: 10.1146/annurev-biochem-061516-045049
Scheiblich, H., Trombly, M., Ramirez, A. & Heneka, M. T. Neuroimmune connections in aging and neurodegenerative diseases. Trends Immunol. 41, 300–312 (2020). DOI: 10.1016/j.it.2020.02.002
DiFiglia, M. et al. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 277, 1990–1993 (1997). DOI: 10.1126/science.277.5334.1990
Neumann, M. et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314, 130–133 (2006). DOI: 10.1126/science.1134108
Power, R., Prado-Cabrero, A., Mulcahy, R., Howard, A. & Nolan, J. M. The role of nutrition for the aging population, implications for cognition and Alzheimer’s disease. Ann. Rev. Food Sci. Technol. 10, 619–639 (2019). DOI: 10.1146/annurev-food-030216-030125
Maiese, K. Taking aim at Alzheimer’s disease through the mammalian target of rapamycin. Ann. Med. 46, 587–596 (2014). DOI: 10.3109/07853890.2014.941921
Hirtz, D. et al. How common are the “common” neurologic disorders? Neurology 68, 326–337 (2007). DOI: 10.1212/01.wnl.0000252807.38124.a3
Yaffe, K. et al. Mild cognitive impairment, dementia, and their subtypes in oldest old women. Arch. Neurol. 68, 631–636 (2011). DOI: 10.1001/archneurol.2011.82
Gandy, S. & DeKosky, S. T. Toward the treatment and prevention of Alzheimer’s disease, rational strategies and recent progress. Annu. Rev. Med. 64, 367–383 (2013). DOI: 10.1146/annurev-med-092611-084441
Maiese, K. Targeting molecules to medicine with mTOR, autophagy and neurodegenerative disorders. Br. J. Clin. Pharmacol. 82, 1245–1266 (2016). DOI: 10.1111/bcp.12804
Long, J. M. & Holtzman, D. M. Alzheimer disease, an update on pathobiology and treatment strategies. Cell 179, 312–339 (2019). DOI: 10.1016/j.cell.2019.09.001
Haass, C., Kaether, C., Thinakaran, G. & Sisodia, S. Trafficking and proteolytic processing of APP. Cold Spring Harb. Perspect. Med. 2, a006270 (2012). DOI: 10.1101/cshperspect.a006270
Naj, A. C. & Schellenberg, G. D. Alzheimer’s Disease Genetics Consortium (ADGC), Genomic variants, genes, and pathways of Alzheimer’s disease, An overview. Am. J. Med. Genet. B Neuropsychiatr. Genet. 174, 5–26 (2017). DOI: 10.1002/ajmg.b.32499
Cirrito, J. R. et al. Endocytosis is required for synaptic activity-dependent release of amyloid-beta in vivo. Neuron 58, 42–51 (2008). DOI: 10.1016/j.neuron.2008.02.003
Sato, C. et al. Tau kinetics in neurons and the human central nervous system. Neuron 97, 1284–1298 (2018). DOI: 10.1016/j.neuron.2018.02.015
He, Z. et al. Amyloid-β plaques enhance Alzheimer’s brain tau-seeded pathologies by facilitating neuritic plaque tau aggregation. Nat. Med. 24, 29–38 (2018). DOI: 10.1038/nm.4443
Wang, L. et al. Evaluation of tau imaging in staging Alzheimer disease and revealing interactions between β-amyloid and tauopathy. JAMA Neurol. 73, 1070–1077 (2016). DOI: 10.1001/jamaneurol.2016.2078
Choi, S. H. et al. A three-dimensional human neural cell culture model of Alzheimer’s disease. Nature 515, 274–278 (2014). DOI: 10.1038/nature13800
Vogel, J. W. et al. Spread of pathological tau proteins through communicating neurons in human Alzheimer’s disease. Nat. Commun. 11, 2612 (2020). DOI: 10.1038/s41467-020-15701-2
Hanseeuw, B. J. et al. Association of amyloid and Tau with cognition in preclinical Alzheimer disease, a longitudinal study. JAMA Neurol. 76, 915–924 (2019). DOI: 10.1001/jamaneurol.2019.1424
Dujardin, S. et al. Tau molecular diversity contributes to clinical heterogeneity in Alzheimer’s disease. Nat. Med. 26, 1256–1263 (2020). DOI: 10.1038/s41591-020-0938-9
Efhymiou, A. G. & Goate, A. M. Late onset Alzheimer’s disease genetics implicates microglial pathways in disease risk. Mol. Neurodegener. 12, 43 (2017). DOI: 10.1186/s13024-017-0184-x
Murphy, M. P. & LeVine, H. III Alzheimer’s disease and the amyloid-beta peptide. J. Alzheimers Dis. 19, 311–323 (2010). DOI: 10.3233/JAD-2010-1221
Mishra, A. K. et al. Aberrant autophagy and Parkinsonism, does correction rescue from disease progression? Mol. Neurobiol. 51, 893–908 (2015). DOI: 10.1007/s12035-014-8744-3
Braczynski, A. K., Schulz, J. B. & Bach, J. P. Vaccination strategies in tauopathies and synucleinopathies. J. Neurochem 143, 467–488 (2017). DOI: 10.1111/jnc.14207
Lashuel, H. A., Overk, C. R., Oueslati, A. & Masliah, E. The many faces of alpha-synuclein, from structure and toxicity to therapeutic target. Nat. Rev. Neurosci. 14, 38–48 (2013). DOI: 10.1038/nrn3406
Dehay, B. et al. Targeting α-synuclein for treatment of Parkinson’s disease, mechanistic and therapeutic considerations. Lancet Neurol. 14, 855–866 (2015). DOI: 10.1016/S1474-4422(15)00006-X
Peng, C., Trojanowski, J. Q. & Lee, V. M. Protein transmission in neurodegenerative disease. Nat. Rev. Neurosci. 16, 199–212 (2020).
Irwin, D. J. et al. Neuropathologic substrates of Parkinson disease dementia. Ann. Neurol. 72, 587–598 (2012). DOI: 10.1002/ana.23659
Sepulcre, J. et al. In vivo tau, amyloid, and gray matter profiles in the aging brain. J. Neurosci. 36, 7364–7374 (2016). DOI: 10.1523/JNEUROSCI.0639-16.2016
Haggerty, T. et al. Hyperphosphorylated Tau in an α-synuclein-overexpressing transgenic model of Parkinson’s disease. Eur. J. Neurosci. 33, 1598–1610 (2011). DOI: 10.1111/j.1460-9568.2011.07660.x
Kirkley, K. S., Popichak, K. A., Afzali, M. F., Legare, M. E. & Tjalkens, R. B. Microglia amplify inflammatory activation of astrocytes in manganese neurotoxicity. J. Neuroinflammation 14, 99 (2017). DOI: 10.1186/s12974-017-0871-0
Tsarouchas, T. M. et al. Dynamic control of proinflammatory cytokines Il-1β and Tnf-α by macrophages in zebrafish spinal cord regeneration. Nat. Commun. 9, 4670 (2018). DOI: 10.1038/s41467-018-07036-w
Walter, J. The triggering receptor expressed on myeloid cells 2, a molecular link of neuroinflammation and neurodegenerative diseases. J. Biol. Chem. 291, 4334–4341 (2016). DOI: 10.1074/jbc.R115.704981
Hong, S. et al. Complement and microglia mediate early synapse loss in Alzheimer mouse models. Science 352, 712–716 (2016). DOI: 10.1126/science.aad8373
Castro-Sanchez, S., Garcia-Yague, A. J., Lopez-Royo, T., Casarejos, M., Lanciego, J. L. & Lastres-Becker, I. Cx3cr1-deficiency exacerbates alpha-synuclein-A53T induced neuroinflammation and neurodegeneration in a mouse model of Parkinson’s disease. Glia 66, 1752–1762 (2018). DOI: 10.1002/glia.23338
Guerreiro, R. & Hardy, J. Genetics of Alzheimer’s disease. Neurotherapeutics 11, 732–737 (2014). DOI: 10.1007/s13311-014-0295-9
Ridge, P. G. et al. Assessment of the genetic variance of late-onset Alzheimer’s disease. Neurobiol. Aging 41, 200.e13–200.e20 (2016). DOI: 10.1016/j.neurobiolaging.2016.02.024
Lardenoije, R. et al. Age-related epigenetic changes in hippocampal subregions of four animal models of Alzheimer’s disease. Mol. Cell. Neurosci. 86, 1–15 (2018). DOI: 10.1016/j.mcn.2017.11.002
Ishii, M. & Iadecola, C. Risk factor for Alzheimer’s disease breaks the blood-brain barrier. Nature 581, 31–32 (2020). DOI: 10.1038/d41586-020-01152-8
Yamazaki, Y., Zhao, N., Caulfield, T. R., Liu, C. C. & Bu, G. Apolipoprotein E and Alzheimer disease, pathobiology and targeting strategies. Nat. Rev. Neurosci. 15, 501–518 (2019).
Sepulcre, J. et al. Neurogenetic contributions to amyloid beta and tau spreading in the human cortex. Nat. Med. 24, 1910–1918 (2018). DOI: 10.1038/s41591-018-0206-4
Calafate, S., Flavin, W., Verstreken, P. & Moechars, D. Loss of Bin1 promotes the propagation of tau pathology. Cell Rep. 17, 931–940 (2016). DOI: 10.1016/j.celrep.2016.09.063
Sims, R. et al. Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer’s disease. Nat. Genet. 49, 1373–1384 (2017). DOI: 10.1038/ng.3916
van der Lee, S. J. et al. A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer’s disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity. Acta Neuropathol. 138, 237–250 (2019). DOI: 10.1007/s00401-019-02030-y
Parhizkar, S. et al. Loss of TREM2 function increases amyloid seeding but reduces plaque-associated ApoE. Nat. Neurosci. 22, 191–204 (2019). DOI: 10.1038/s41593-018-0296-9
Morita, N. et al. GPR31-dependent dendrite protrusion of intestinal CX3CR1+ cells by bacterial metabolites. Nature 566, 110–114 (2019). DOI: 10.1038/s41586-019-0884-1
Bolós, M. et al. Absence of CX3CR1 impairs the internalization of Tau by microglia. Mol. Neurodegener. 12, 59 (2017). DOI: 10.1186/s13024-017-0200-1
Bhaskar, K., Konerth, M., Kokiko-Cochran, O. N., Cardona, A., Ransohoff, R. M. & Lamb, B. T. Regulation of tau pathology by the microglial fractalkine receptor. Neuron 68, 19–31 (2010). DOI: 10.1016/j.neuron.2010.08.023
Leonardi, I. et al. CX3CR1+ mononuclear phagocytes control immunity to intestinal fungi. Science 359, 232–236 (2018). DOI: 10.1126/science.aao1503
Pao, P. C. et al. HDAC1 modulates OGG1-initiated oxidative DNA damage repair in the aging brain and Alzheimer’s disease. Nat. Commun. 11, 2484 (2020). DOI: 10.1038/s41467-020-16361-y
Itzhaki, R. F. et al. Whittum-Hudson, microbes and Alzheimer’s disease. J. Alzheimers Dis. 51, 979–984 (2016). DOI: 10.3233/JAD-160152
Steger, M. et al. Phosphoproteomics reveals that Parkinson’s disease kinase LRRK2 regulates a subset of Rab GTPases. Elife 5, e12813 (2016). DOI: 10.7554/eLife.12813
Bae, E. J. et al. LRRK2 kinase regulates alphasynuclein propagation via RAB35 phosphorylation. Nat. Commun. 9, 3465 (2018). DOI: 10.1038/s41467-018-05958-z
Kluss, J. H., Mamais, A. & Cookson, M. R. LRRK2 links genetic and sporadic Parkinson’s disease. Biochem. Soc. Trans. 47, 651–661 (2019). DOI: 10.1042/BST20180462
Abeliovich, A. & Gitler, A. D. Defects in trafficking bridge Parkinson’s disease pathology and genetics. Nature 539, 207–216 (2016). DOI: 10.1038/nature20414
Beers, D. R. & Appel, S. H. Immune dysregulation in amyotrophic lateral sclerosis, mechanisms and emerging therapies. Lancet Neurol. 18, 211–220 (2019). DOI: 10.1016/S1474-4422(18)30394-6
Goldman, S. M. Environmental toxins and Parkinson’s disease. Annu. Rev. Pharmacol. Toxicol. 54, 141–164 (2014). DOI: 10.1146/annurev-pharmtox-011613-135937
GBD 2015 Mortality and Causes of Death Collaborators. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015, a systematic analysis for the Global Burden of Disease Study 2015. Lancet 388, 1459–1544 (2016). DOI: 10.1016/S0140-6736(16)31012-1
Fleming, S. M. Mechanisms of gene-environment interactions in Parkinson’s disease. Curr. Environ. Health Rep. 4, 192–199 (2017). DOI: 10.1007/s40572-017-0143-2
Tanner, C. M. et al. Rotenone, paraquat, and Parkinson’s disease. Environ. Health Perspect. 119, 866–872 (2011). DOI: 10.1289/ehp.1002839
Sarkar, S. et al. Manganese activates NLRP3 inflammasome signaling and propagates exosomal release of ASC in microglial cells. Sci. Signal. 12, eaat9900 (2019). DOI: 10.1126/scisignal.aat9900
Kawahara, M., Kato-Negishi, M. & Tanaka, K. Cross talk between neurometals and amyloidogenic proteins at the synapse and the pathogenesis of neurodegenerative diseases. Metallomics 9, 619–633 (2017). DOI: 10.1039/C7MT00046D
Wang, H. et al. iTRAQ-based proteomic technology revealed protein perturbations in intestinal mucosa from manganese exposure in rat models. RSC Adv. 7, 31745–31758 (2017). DOI: 10.1039/C7RA03358C
Wang, H. et al. The gut microbiota confers protection in the CNS against neurodegeneration induced by manganism. Biomed. Pharmacother. 127, 110150 (2020). DOI: 10.1016/j.biopha.2020.110150
Jenkitkasemwong, S. et al. SLC39A14 deficiency alters manganese homeostasis and excretion resulting in brain manganese accumulation and motor deficits in mice. Proc. Natl Acad. Sci. USA 115, E1769–E1778 (2018). DOI: 10.1073/pnas.1720739115
Harischandra, D. S. et al. Manganese promotes the aggregation and prion-like cell-to-cell exosomal transmission of α-synuclein. Sci. Signal. 12, eaau4543 (2019). DOI: 10.1126/scisignal.aau4543
Mirza, A., King, A., Troakes, C. & Exley, C. Aluminium in brain tissue in familial Alzheimer’s disease. J. Trace Elem. Med. Biol. 40, 30–36 (2017). DOI: 10.1016/j.jtemb.2016.12.001
Garza–Lombó, C., Posadas, Y., Quintanar, L., Gonsebatt, M. E. & Franco, R. Neurotoxicity linked to dysfunctional metal ion homeostasis and xenobiotic metal exposure, Redox signaling and oxidative stress. Antioxid. Redox Signal. 28, 1669–1703 (2018). DOI: 10.1089/ars.2017.7272
Mold, M., Linhart, C., Gómez-Ramírez, J., Villegas-Lanau, A. & Exley, C. Aluminum and amyloid-β in familial Alzheimer’s disease. J. Alzheimers Dis. 73, 1627–1635 (2020). DOI: 10.3233/JAD-191140
Lukiw, W. J. et al. Aluminum in neurological disease - a 36 year multicenter study. J. Alzheimers Dis. Parkinsonism 8, 457 (2019).
Mezzaroba, L., Alfieri, D. F., Colado Simão, A. N. & Vissoci Reiche, E. M. The role of zinc, copper, manganese and iron in neurodegenerative diseases. Neurotoxicology 74, 230–241 (2019). DOI: 10.1016/j.neuro.2019.07.007
Farina, M., Avila, D. S., Da Rocha, J. B. & Aschner, M. Metals, oxidative stress and neurodegeneration, A focus on iron, manganese and mercury. Neurochem. Int. 62, 575–594 (2013). DOI: 10.1016/j.neuint.2012.12.006
Rodrigues, E. G. et al. Neurodevelopmental outcomes among 2- to 3-year-old children in Bangladesh with elevated blood lead and exposure to arsenic and manganese in drinking water. Environ. Health 15, 1–9 (2016). DOI: 10.1186/s12940-016-0127-y
Cholanians, A. B. et al. Arsenic induces accumulation of α-synuclein, Implications for synucleinopathies and neurodegeneration. Toxicol. Sci. 153, 271–281 (2016). DOI: 10.1093/toxsci/kfw117
Karri, V. et al. Differential protein expression of hippocampal cells associated with heavy metals (Pb, As, and MeHg) neurotoxicity: deepening into the molecular mechanism of neurodegenerative diseases. J. Proteom. 187, 106–125 (2018). DOI: 10.1016/j.jprot.2018.06.020
Kim, K. H., Kabir, E. & Jahan, S. A. Exposure to pesticides and the associated human health effects. Sci. Total Environ. 575, 525–535 (2017). DOI: 10.1016/j.scitotenv.2016.09.009
Won, J. H., Park, S., Hong, S., Son, S. & Yu, J. W. Rotenone-induced impairment of mitochondrial electron transport chain confers a selective priming signal for NLRP3 inflammasome activation. J. Biol. Chem. 290, 27425–27437 (2015). DOI: 10.1074/jbc.M115.667063
Martinez, E. M. et al. Editor’s highlight, Nlrp3 is required for inflammatory changes and nigral cell loss resulting from chronic intragastric rotenone exposure in mice. Toxicol. Sci. 159, 64–75 (2017). DOI: 10.1093/toxsci/kfx117
Liu, Z. et al. Silymarin attenuated paraquat-induced cytotoxicity in macrophage by regulating Trx/TXNIP complex, inhibiting NLRP3 inflammasome activation and apoptosis. Toxicol. Vitr. 46, 265–272 (2018). DOI: 10.1016/j.tiv.2017.10.017
Chen, L., Na, R., Boldt, E. & Ran, Q. NLRP3 inflammasome activation by mitochondrial reactive oxygen species plays a key role in long-term cognitive impairment induced by paraquat exposure. Neurobiol. Aging 36, 2533–2543 (2015). DOI: 10.1016/j.neurobiolaging.2015.05.018
Li, W. & Ehrich, M. Transient alterations of the bloodbrain barrier tight junction and receptor potential channel gene expression by chlorpyrifos. J. Appl. Toxicol. 33, 1187–1191 (2013). DOI: 10.1002/jat.2762
Ransohoff, R. M. How neuroinflammation contributes to neurodegeneration. Science 353, 777–783 (2016). DOI: 10.1126/science.aag2590
Cannon, J. R. & Greenamyre, J. T. Gene-environment interactions in Parkinson’s disease: specific evidence in humans and mammalian models. Neurobiol. Dis. 57, 38–46 (2013). DOI: 10.1016/j.nbd.2012.06.025
Karl, J. P. et al. Effects of psychological, environmental and physical stressors on the gut microbiota. Front. Microbiol. 9, 2013 (2018). DOI: 10.3389/fmicb.2018.02013
Gubert, C., Kong, G., Renoir, T. & Hannan, A. J. Exercise, diet and stress as modulators of gut microbiota: Implications for neurodegenerative diseases. Neurobiol. Dis. 134, 104621 (2020). DOI: 10.1016/j.nbd.2019.104621
Xia, J. Z. et al. Chronic exposure to low concentrations of lead induces metabolic disorder and dysbiosis of the gut microbiota in mice. Sci. Total Environ. 631–632, 439–448 (2018). DOI: 10.1016/j.scitotenv.2018.03.053
Feng, P. et al. A Review on gut remediation of selected environmental contaminants: possible roles of probiotics and gut microbiota. Nutrients 11, 22 (2019). DOI: 10.3390/nu11010022
Wang, H. et al. The gut microbiota attenuate neuroinflammation in manganese exposure by inhibiting cerebral NLRP3 inflammasome. Biomed. Pharmacother. 129, 110449 (2020). DOI: 10.1016/j.biopha.2020.110449
Nasuti, C. et al. Neonatal exposure to permethrin pesticide causes lifelong fear and spatial learning deficits and alters hippocampal morphology of synapses. J. Neurodev. Disord. 6, 1–11 (2014). DOI: 10.1186/1866-1955-6-7
Beaumont, M. et al. Heritable components of the human fecal microbiome are associated with visceral fat. Genome Biol. 17, 189 (2016). DOI: 10.1186/s13059-016-1052-7
Turpin, W. et al. Association of host genome with intestinal microbial composition in a large healthy cohort. Nat. Genet. 48, 1413–1417 (2016). DOI: 10.1038/ng.3693
Matsumoto, L. et al. CpG demethylation enhances alpha-synuclein expression and affects the pathogenesis of Parkinson’s disease. PLoS ONE 5, e15522 (2010). DOI: 10.1371/journal.pone.0015522
Friedland, R. P. Mechanisms of molecular mimicry involving the microbiota in neurodegeneration. J. Alzheimers Dis. 45, 349–362 (2015). DOI: 10.3233/JAD-142841
Tsuang, D. et al. APOE ε4 increases risk for dementia in pure synucleinopathies. JAMA Neurol. 70, 223–228 (2013). DOI: 10.1001/jamaneurol.2013.600
Vascellari, S. et al. Genetic variants of TAS2R38 bitter taste receptor associate with distinct gut microbiota traits in Parkinson’s disease: a pilot study. Int. J. Biol. Macromol. 165, 665–674 (2020). DOI: 10.1016/j.ijbiomac.2020.09.056
Goodrich, J. K. et al. Human genetics shape the gut microbiome. Cell 159, 789–799 (2014). DOI: 10.1016/j.cell.2014.09.053
Tran, T. T. T. et al. APOE genotype influences the gut microbiome structure and function in humans and mice: relevance for Alzheimer’s disease pathophysiology. FASEB J. 33, 8221–8231 (2019). DOI: 10.1096/fj.201900071R
Parikh, I. J. et al. Murine gut microbiome association with APOE alleles. Front Immunol. 11, 200 (2020). DOI: 10.3389/fimmu.2020.00200
Guardia-Escote, L. et al. APOE genotype and postnatal chlorpyrifos exposure modulate gut microbiota and cerebral short-chain fatty acids in preweaning mice. Food Chem. Toxicol. 135, 110872 (2020). DOI: 10.1016/j.fct.2019.110872
Di Ciaula, A., Stella, A., Bonfrate, L., Wang, D. Q. H. & Portincasa, P. Gut microbiota between environment and genetic background in familial Mediterranean fever (FMF). Genes 11, 1041 (2020). DOI: 10.3390/genes11091041
David, L. A. et al. Diet rapidly and reproducibly alters the human gut microbiome. Nature 505, 559–563 (2014). DOI: 10.1038/nature12820
Faith, J. J. et al. The long-term stability of the human gut microbiota. Science 341, 1237439 (2013). DOI: 10.1126/science.1237439
Ridaura, V. K. et al. Gut microbiota from twins discordant for obesity modulate metabolism in mice. Science 341, 1241214 (2013). DOI: 10.1126/science.1241214
Vaughn, A. C. et al. Energy-dense diet triggers changes in gut microbiota, reorganization of gutbrain vagal communication and increases body fat accumulation. Acta Neurobiol. Exp. 77, 18–30 (2017).
Wu, G. D. et al. Linking long-term dietary patterns with gut microbial enterotypes. Science 334, 105–108 (2011). DOI: 10.1126/science.1208344
Long-Smith, C. et al. Microbiota-gut-brain axis, new therapeutic opportunities. Annu. Rev. Pharmacol. Toxicol. 60, 477–502 (2020). DOI: 10.1146/annurev-pharmtox-010919-023628
Cryan, J. F., O’Riordan, K. J., Sandhu, K., Peterson, V. & Dinan, T. G. The gut microbiome in neurological disorders. Lancet Neurol. 19, 179–194 (2020). DOI: 10.1016/S1474-4422(19)30356-4
Cattaneo, A. et al. Association of brain amyloidosis with pro-inflammatory gut bacterial taxa and peripheral inflammation markers in cognitively impaired elderly. Neurobiol. Aging 49, 60–68 (2017). DOI: 10.1016/j.neurobiolaging.2016.08.019
Hilton, D. et al. Accumulation of alpha-synuclein in the bowel of patients in the pre-clinical phase of Parkinson’s disease. Acta Neuropathol. 127, 235–241 (2014). DOI: 10.1007/s00401-013-1214-6
Stilling, R. M., Bordenstein, S. R., Dinan, T. G. & Cryan, J. F. Friends with social benefits, hostmicrobe interactions as a driver of brain evolution and development? Front. Cellular Infect. Microbiol 4, 147 (2014).
Stilling, R. M., Dinan, T. G. & Cryan, J. F. Microbial genes, brain & behaviour-epigenetic regulation of the gut-brain axis. Genes Brain Behav. 13, 69–86 (2014). DOI: 10.1111/gbb.12109
Zhang, L. S. & Davies, S. S. Microbial metabolism of dietary components to bioactive metabolites: opportunities for new therapeutic interventions. Genome Med. 8, 46 (2016). DOI: 10.1186/s13073-016-0296-x
Cryan, J. F. et al. The microbiota-gut-brain axis. Physiol. Rev. 99, 1877–2013 (2019). DOI: 10.1152/physrev.00018.2018
Furness, J. B. The enteric nervous system and neurogastroenterology. Nat. Rev. Gastroenterol. Hepatol. 9, 286–294 (2012). DOI: 10.1038/nrgastro.2012.32
Bellono, N. W. et al. Enterochromaffin cells are gut chemosensors that couple to sensory neural pathways. Cell 170, 185–198 (2017). DOI: 10.1016/j.cell.2017.05.034
Sperringer, J. E., Addington, A. & Hutson, S. M. Branched-chain amino acids and brain metabolism. Neurochem. Res. 42, 1697–1709 (2017). DOI: 10.1007/s11064-017-2261-5
Zhang, S., Zeng, X., Ren, M., Mao, X. & Qiao, S. Novel metabolic and physiological functions of branched chain amino acids: a review. J. Anim. Sci. Biotechnol. 8, 10 (2017). DOI: 10.1186/s40104-016-0139-z
Neinast, M., Murashige, D. & Arany, Z. Branched chain amino acids. Annu. Rev. Physiol. 81, 139–164 (2019). DOI: 10.1146/annurev-physiol-020518-114455
Silva, Y. P., Bernardi, A. & Frozza, R. L. The role of short-chain fatty acids from gut microbiota in gut-brain communication. Front. Endocrinol. 11, 25 (2020). DOI: 10.3389/fendo.2020.00025
Dalile, B., Van Oudenhove, L., Vervliet, B. & Verbeke, K. The role of short-chain fatty acids in microbiota-gut-brain communication. Nat. Rev. Gastroenterol. Hepatol. 16, 461–478 (2019). DOI: 10.1038/s41575-019-0157-3
Gill, P. A., van Zelm, M. C., Muir, J. G. & Gibson, P. R. Review article, short chain fatty acids as potential therapeutic agents in human gastrointestinal and inflammatory disorders. Aliment. Pharmacol. Ther. 48, 15–34 (2018). DOI: 10.1111/apt.14689
Erny, D., Hrabě de Angelis, A. L. & Prinz, M. Communicating systems in the body, how microbiota and microglia cooperate. Immunology 150, 7–15 (2017). DOI: 10.1111/imm.12645
Unger, M. M. et al. Short chain fatty acids and gut microbiota differ between patients with Parkinson’s disease and age-matched controls. Parkinsonism Relat. Disord. 32, 66–72 (2016). DOI: 10.1016/j.parkreldis.2016.08.019
Zhang, L. et al. Altered gut microbiota in a mouse model of Alzheimer’s disease. J. Alzheimers Dis. 60, 1241–1257 (2017). DOI: 10.3233/JAD-170020
Overduin, J., Schoterman, M. H., Calame, W., Schonewille, A. J. & Ten Bruggencate, S. J. Dietary galacto-oligosaccharides and calcium, effects on energy intake, fat-pad weight and satiety-related, gastrointestinal hormones in rats. Br. J. Nutr. 109, 1338–1348 (2013). DOI: 10.1017/S0007114512003066
Taipa, R. et al. Proinflammatory and anti–inflammatory cytokines in the CSF of patients with Alzheimer’s disease and their correlation with cognitive decline. Neurobiol. Aging 76, 125–132 (2019). DOI: 10.1016/j.neurobiolaging.2018.12.019
Morales, I., Farías, G. & Maccioni, R. B. Neuroimmunomodulation in the pathogenesis of Alzheimer’s disease. Neuroimmunomodulation 17, 202–204 (2010). DOI: 10.1159/000258724
Heneka, M. T., Kummer, M. P. & Latz, E. Innate immune activation in neurodegenerative disease. Nat. Rev. Immunol. 14, 463–477 (2014). DOI: 10.1038/nri3705
Eisele, Y. S. & Duyckaerts, C. Propagation of Aβ pathology: hypotheses, discoveries, and yet unresolved questions from experimental and human brain studies. Acta Neuropathol. 131, 5–25 (2016). DOI: 10.1007/s00401-015-1516-y
Sun, Y. et al. Intra-gastrointestinal amyloid-β1-42 oligomers perturb enteric function and induce Alzheimer’s disease pathology. J. Physiol. 598, 4209–4223 (2020). DOI: 10.1113/JP279919
Cho, I. & Blaser, M. J. The human microbiome, at the interface of health and disease. Nat. Rev. Genet. 13, 260–270 (2012). DOI: 10.1038/nrg3182
Sampson, T. R. et al. Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson’s disease. Cell 167, 1469–1480 (2016). DOI: 10.1016/j.cell.2016.11.018
Sharon, G. et al. Human gut microbiota from Autism spectrum disorder promote behavioral symptoms in mice. Cell 177, 1600–1618 (2019). DOI: 10.1016/j.cell.2019.05.004
Zheng, P. et al. The gut microbiome from patients with schizophrenia modulates the glutamate-glutamine-GABA cycle and schizophrenia-relevant behaviors in mice. Sci. Adv. 5, eaau8317 (2019). DOI: 10.1126/sciadv.aau8317
De Palma, G. et al. Transplantation of fecalmicrobiota from patients with irritable bowel syndrome alters gut function and behavior in recipient mice. Sci. Transl. Med 9, eaaf6397 (2017). DOI: 10.1126/scitranslmed.aaf6397
Gupta, A. & Khanna, S. Fecal microbiota transplantation. JAMA 318, 102 (2017). DOI: 10.1001/jama.2017.6466
Makkawi, S., Camara-Lemarroy, C. & Metz, L. Fecal microbiota transplantation associated with 10 years of stability in a patient with SPMS. Neurol. Neuroimmunol. Neuroinflamm. 5, e459 (2018). DOI: 10.1212/NXI.0000000000000459
Huang, H. et al. Fecal microbiota transplantation to treat Parkinson’s disease with constipation, a case report. Medicine 98, e16163 (2019). DOI: 10.1097/MD.0000000000016163
Xue, L. J. et al. Fecal microbiota transplantation therapy for Parkinson’s disease: a preliminary study. Medicine 99, e22035 (2020). DOI: 10.1097/MD.0000000000022035
He, Z. et al. Fecal microbiota transplantation cured epilepsy in a case with Crohn’s disease, the first report. World J. Gastroenterol. 23, 3565–3568 (2017). DOI: 10.3748/wjg.v23.i19.3565
Aabed, K. et al. Ameliorative effect of probiotics [Lactobacillus paracaseii and Protexin(R)] and prebiotics (propolis and bee pollen) on clindamycin and propionic acid-induced oxidative stress and altered gut microbiota in a rodent model of autism.Cell. Mol. Biol. 65,1–7 (2019). DOI: 10.14715/cmb/2019.65.1.1
Rooks, M. G. & Garrett, W. S. Gut microbiota, metabolites and host immunity. Nat. Rev. Immunol. 16, 341–352 (2016). DOI: 10.1038/nri.2016.42
Matcovitch-Natan, O. et al. Microglia development follows a stepwise program to regulate brain homeostasis. Science 353, aad8670 (2016). DOI: 10.1126/science.aad8670
Del Tredici, K. & Braak, H. A not entirely benign procedure: progression of Parkinson’s disease. Acta Neuropathol. 115, 379–384 (2008). DOI: 10.1007/s00401-008-0355-5
Wallen, Z. D. et al. Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens. NPJ Parkinsons Dis. 6, 11 (2020). DOI: 10.1038/s41531-020-0112-6
Sun, M. F. et al. Neuroprotective effects of fecal microbiota transplantation on MPTP-induced Parkinson’s disease mice, gut microbiota, glial reaction and TLR4/TNF-alpha signaling pathway. Brain Behav. Immun. 70, 48–60 (2018). DOI: 10.1016/j.bbi.2018.02.005
Olson, C. A. et al. The gut microbiota mediates the anti-seizure effects of the ketogenic diet. Cell 173, 1728–1741 (2018). DOI: 10.1016/j.cell.2018.04.027
Zhuang, Z. Q. et al. Gut microbiota is altered in patients with Alzheimer’s disease. J. Alzheimers Dis. 63, 1337–1346 (2018). DOI: 10.3233/JAD-180176
Manderino, L. et al. Preliminary evidence for an association between the composition of the gut microbiome and cognitive function in neurologically healthy older adults. J. Int. Neuropsychol. Soc. 23, 700–705 (2017). DOI: 10.1017/S1355617717000492
Lin, C. et al. Microbiota-gut-brain axis and toll-like receptors in Alzheimer’s disease. Comput. Struct. Biotechnol. J. 17, 1309–1317 (2019). DOI: 10.1016/j.csbj.2019.09.008
Fujii, Y. et al. Fecal metabolite of a gnotobiotic mouse transplanted with gut microbiota from a patient with Alzheimer’s disease. Biosc. Biotechnol. Biochem. 83, 2144–2152 (2019). DOI: 10.1080/09168451.2019.1644149
Kim, M. S. et al. Transfer of a healthy microbiota reduces amyloid and tau pathology in an Alzheimer’s disease animal model. Gut 69, 283–294 (2020). DOI: 10.1136/gutjnl-2018-317431
Zhan, G. et al. Abnormal gut microbiota composition contributes to cognitive dysfunction in SAMP8 mice. Aging 10, 1257–1267 (2018). DOI: 10.18632/aging.101464
Coryell, M., McAlpine, M., Pinkham, N. V., McDermott, T. R. & Walk, S. T. The gut microbiome is required for full protection against acute arsenic toxicity in mouse models. Nat. Commun. 9, 5424 (2018). DOI: 10.1038/s41467-018-07803-9
Allegretti, J. R., Mullish, B. H., Kelly, C. & Fischer, M. The evolution of the use of faecal microbiota transplantation and emerging therapeutic indications. Lancet 394, 420–431 (2019). DOI: 10.1016/S0140-6736(19)31266-8
Gupta, S., Mullish, B. H. & Allegretti, J. R. Fecal microbiota transplantation: the evolving risk landscape. Am. J. Gastroenterol. 116, 647–656 (2021). DOI: 10.14309/ajg.0000000000001075
Baxter, M. & Colville, A. Adverse events in faecal microbiota transplant: a review of the literature. J. Hosp. Infect. 92, 117–127 (2016). DOI: 10.1016/j.jhin.2015.10.024
Cheng, Y. W. et al. Fecal microbiota transplantation for the treatment of recurrent and severe Clostridium difficile infection in solid organ transplant recipients: a multicenter experience. Am. J. Transpl. 19, 501–511 (2019). DOI: 10.1111/ajt.15058
Wang, W. et al. Detection of SARS-CoV-2 in different types of clinical specimens. JAMA 323, 1843–1844 (2020).
Xiao, F. et al. Evidence for gastrointestinal infection of SARS-CoV-2. Gastroenterology 158, 1831–1833.e3 (2020). DOI: 10.1053/j.gastro.2020.02.055
